EVERGREEN THERAPEUTICS
Evergreen Therapeutics engages in the research and development of clinical drugs in the field of immunity and ophthalmology.
EVERGREEN THERAPEUTICS
Social Links:
Industry:
Health Care Pharmaceutical Product Research Therapeutics
Founded:
2019-08-01
Address:
Shenzhen, Guangdong, China
Country:
China
Website Url:
http://www.egpharm.com
Total Employee:
1+
Status:
Active
Contact:
+86 18688785126
Current Employees Featured
Founder
Official Site Inspections
http://www.egpharm.com Semrush global rank: 8.72 M Semrush visits lastest month: 261
- Host name: 139.196.228.59
- IP address: 139.196.228.59
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Evergreen Therapeutics"
关于我们-埃格林医药 - egpharm.com
埃格林医药（Evergreen Therapeutics）是一家行业领先的用AI赋能临床研发的国际化创新药企。公司于2019年成立，在中国深圳和美国马里兰均设有分支机构，并拥有一支汇聚临床医学， …See details»
About-Evergreen Therapeutics, Inc. - en.egpharm.com
Evergreen Therapeutics is a Maryland-based innovative biopharmaceutical company established in 2019 with artificial intelligence (AI) as one of its core technologies. we have a cross-border …See details»
Evergreen Therapeutics, Inc.
Evergreen Therapeutics is currently developing drug candidates for the treatment of a variety of clinical indications, including AMD (age-related macular degeneration, both dry and wet subtypes), endometrial cancer (via …See details»
Shenzhen Eglin Pharmaceutical Co., Ltd - Drug pipelines, Patents ...
Www.egpharm.com. Last update 19 Sep 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. Eye Diseases. ... The …See details»
Evergreen Therapeutics, Inc. | LinkedIn
Evergreen Therapeutics, Inc. | 282 followers on LinkedIn.See details»
Shenzhen Eglin Pharmaceutical Co., Ltd - synapse.zhihuiya.com
了解Shenzhen Eglin Pharmaceutical Co., Ltd (深圳埃格林医药有限公司)公司的药物管线，治疗领域，技术平台，以及它的211篇新闻，疾病领域:内分泌与代谢疾病，免疫系统疾病，神经系统 …See details»
Technology And Pipeline-Evergreen Therapeutics, Inc.
EG-009 oral drug will mainly be used to treat cytokine storms in hospitalized COVID-19 patients. According to the latest statistics from the World Health Organization, more than 200 million …See details»
加入我们-埃格林医药 - egpharm.com
有意者请投递简历至 [email protected]。 公司理念 埃格林医药在关注临床需求的同时，以质量求生存、促发展，诚信经营、规范运作，力争打造成为最具活力的中国创新医药企 …See details»
Evergreen Therapeutics, Inc. Announces Agreement with ICON plc …
Jun 18, 2021 Dr. David Du, CEO of Evergreen Therapeutics, commented, “Evergreen Therapeutics is pleased to partner with ICON plc, the world’s second largest clinical trial …See details»
Evergreen Therapeutics, Inc. Announces Agreement with ICON
Jun 18, 2021 Contact Data For more information, please contact: Company: Evergreen Therapeutics, Inc. China： 33A, Media Finance Center Shenzhen, Guangdong Province, PRC …See details»
News-Evergreen Therapeutics, Inc. - en.egpharm.com
On September 15, the "Ernst & Young Fudan Most Potential Enterprise Award Ceremony 2022 and High Growth Enterprise Theme Seminar" hosted by Ernst & Young, the world's leading …See details»
研发管线-埃格林医药 - egpharm.com
埃格林医药关注迫切临床需求，在免疫相关的治疗药物和眼科药物方面拥有丰富的产品管线。埃格林目前正在研发10种临床适应症的候选药品，涵盖包括细胞因子风暴、子宫内膜癌、先兆子痫 …See details»
Join Us-Evergreen Therapeutics, Inc. - en.egpharm.com
Please send your resume to [email protected]. Company Value. A new round of medical and health system reform will bring historical opportunities to the development of the company. …See details»
EG-007 and Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection …
Sep 22, 2021 Email: [email protected]; Study Contact Backup. Name: Charles Lee, M.D., Ph.D. Phone Number: 2404064016; Email: [email protected]; Participation Criteria. …See details»
李长青博士加入深圳埃格林医药，担任首席医学官-埃格林医药
2021年7月19日，深圳埃格林医药宣布任命李长青博士为公司首席医学官（cmo），全面负责公司的全球新药开发工作。李博士的加盟将进一步完善研究团队建设，构建更高效的临床试验医学 …See details»
拿捏FDA的心思，它有望成为国内首家药物上市的AI药企？ - 知乎
“第一是关注临床需求，第二是面向国际市场， 第三是高效开发，第四是迅速进入临床试验。”——埃格林医药创始人 杜涛 智药局曾经统计过中国超80家ai制药企业的创始背景，发现其绝 …See details»
The U.S. FDA Has Granted Clearance to Evergreen's EG-007 for …
On August 10, 2021, Shenzhen Evergreen Pharmaceutical Co., Ltd. announced that its innovative drug candidate EG-007 has been approved by the U.S. Food and Drug Administration (FDA) …See details»
埃格林医药美国团队首次线下会议召开，回顾成就，展望未来
美东时间2021年10月18日至19日，埃格林医药有限公司在美国马里兰州贝塞斯达举行了疫情以来第一次美国总部线下会议。董事长杜涛博士、首席执行官杜新博士、首席医疗官李长青博士 …See details»
Another Evergreen Me-Only Drug Cleared by the FDA for Phase II …
On February 4, 2022, Evergreen Therapeutics Co., Ltd. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") announced that an oral drug for the treatment of dry macular …See details»